Why carry out this study? |
Patients with relapsed/refractory multiple myeloma (RRMM) have a poor prognosis, indicating a need for new, efficacious, and well-tolerated treatment options to improve outcomes. |
The ongoing, single-arm MonumenTAL-1 (NCT03399799, NCT04636552) study is investigating the efficacy and safety of talquetamab, a T cell-redirecting bispecific antibody targeting GPRC5D × CD3, which was recently approved in patients with RRMM who are triple-class-exposed (TCE; i.e., prior treatment with an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody). |
The objective of this study was to compare outcomes in patients with TCE RRMM who were treated with either of two doses of talquetamab (0.4 mg/kg weekly or 0.8 mg/kg every other week) in MonumenTAL-1 vs. patients treated with TCE RRMM who were treated with real-world physician’s choice of therapy from the prospective, observational LocoMMotion and MoMMent studies. |
What was learned from the study? |
Patients treated with either dose of talquetamab in MonumenTAL-1 had significant improvements in most efficacy outcomes compared with an eligibility-matched patient cohort treated with real-world physician’s choice of therapy. |
The results indicate that talquetamab may provide a highly effective treatment option for patients with TCE RRMM, who have historically limited options. |
Introduction
Methods
Patient Populations
Efficacy Endpoints
Statistical Analyses
Results
Patient Characteristics
Covariate | Observed | Talquetamab 0.4 mg/kg QW, n (%) (n = 143) | ATT-adjusted | Talquetamab 0.8 mg/kg Q2W, n (%) (n = 145) | ATT-adjusted | ||
---|---|---|---|---|---|---|---|
RWPC cohort, n (%) (n = 177) | RWPC cohort, n (%) (n = 177) | SMD | RWPC cohort, n (%) (n = 177) | SMD | |||
Refractory statusa | 0.099 | 0.115 | |||||
≤ Doubleb | 50 (28.2) | 37 (25.9) | 41 (23.0) | 45 (31.0) | 60 (33.8) | ||
Triplec | 42 (23.7) | 16 (11.2) | 17 (9.7) | 24 (16.6) | 26 (14.6) | ||
Quadrupled | 53 (29.9) | 48 (33.6) | 61 (34.4) | 41 (28.3) | 44 (24.6) | ||
Pentae | 32 (18.1) | 42 (29.4) | 58 (32.9) | 35 (24.1) | 48 (26.9) | ||
ISS stage at study entry | 0.115 | 0.089 | |||||
I | 70 (39.5) | 62 (43.4) | 69 (38.8) | 65 (44.8) | 76 (42.9) | ||
II | 71 (40.1) | 53 (37.1) | 66 (37.5) | 45 (31.0) | 51 (29.1) | ||
III | 36 (20.3) | 28 (19.6) | 42 (23.7) | 35 (24.1) | 50 (28.0) | ||
Time to progression in previous line | 0.139 | 0.095 | |||||
< 3 months | 29 (16.4) | 44 (30.8) | 66 (37.4) | 41 (28.3) | 58 (32.6) | ||
≥ 3 months | 148 (83.6) | 99 (69.2) | 111 (62.6) | 104 (71.7) | 119 (67.4) | ||
Extramedullary diseasef | 0.097 | 0.122 | |||||
Yes | 19 (10.7) | 33 (23.1) | 48 (27.3) | 37 (25.5) | 55 (31.0) | ||
No | 158 (89.3) | 110 (76.9) | 129 (72.7) | 108 (74.5) | 122 (69.0) | ||
Number of previous LOTs | 0.032 | 0.102 | |||||
≤ 4 | 104 (58.8) | 64 (44.8) | 76 (43.1) | 69 (47.6) | 75 (42.5) | ||
> 4 | 73 (41.2) | 79 (55.2) | 101 (56.9) | 76 (52.4) | 102 (57.5) | ||
Years since diagnosis | 0.039 | 0.133 | |||||
< 6 | 77 (43.5) | 64 (44.8) | 76 (42.8) | 67 (46.2) | 70 (39.6) | ||
≥ 6 | 100 (56.5) | 79 (55.2) | 101 (57.2) | 78 (53.8) | 107 (60.4) | ||
Average duration of prior lines | 0.046 | 0.098 | |||||
< 10 months | 27 (15.3) | 25 (17.5) | 33 (18.6) | 37 (25.5) | 45 (25.5) | ||
10–14 months | 44 (24.9) | 41 (28.7) | 53 (29.7) | 35 (24.1) | 36 (20.3) | ||
≥ 15 months | 106 (59.9) | 77 (53.8) | 91 (51.6) | 73 (50.3) | 96 (54.3) | ||
Age | 0.080 | 0.095 | |||||
< 65 years | 54 (30.5) | 65 (45.5) | 73 (41.5) | 63 (43.4) | 69 (38.8) | ||
≥ 65 years | 123 (69.5) | 78 (54.5) | 104 (58.5) | 82 (56.6) | 108 (61.2) | ||
Hemoglobin (g/dL) | 0.144 | 0.026 | |||||
< 12 | 122 (68.9) | 110 (76.9) | 146 (82.7) | 113 (77.9) | 140 (79.0) | ||
≥ 12 | 55 (31.1) | 33 (23.1) | 31 (17.3) | 32 (22.1) | 37 (21.0) | ||
LDH (units/L) | 0.008 | 0.091 | |||||
< 280 | 122 (68.9) | 108 (75.5) | 133 (75.2) | 111 (76.6) | 142 (80.3) | ||
≥ 280 | 55 (31.1) | 35 (24.5) | 44 (24.8) | 34 (23.4) | 35 (19.7) | ||
Creatinine clearance (mL/min) | 0.145 | 0.210 | |||||
< 60 | 43 (24.3) | 40 (28.0) | 43 (24.3) | 45 (31.0) | 40 (22.5) | ||
60 to < 90 | 84 (47.5) | 72 (50.3) | 85 (48.0) | 68 (46.9) | 87 (49.2) | ||
≥ 90 | 50 (28.2) | 31 (21.7) | 49 (27.7) | 32 (22.1) | 50 (28.3) | ||
ECOG PS | 0.005 | 0.043 | |||||
0 | 42 (23.7) | 44 (30.8) | 55 (31.0) | 56 (38.6) | 72 (40.7) | ||
1–2 | 135 (76.3) | 99 (69.2) | 122 (69.0) | 89 (61.4) | 105 (59.3) | ||
Sex | 0.123 | 0.096 | |||||
Male | 96 (54.2) | 78 (54.5) | 86 (48.4) | 83 (57.2) | 93 (52.5) | ||
Female | 81 (45.8) | 65 (45.5) | 91 (51.6) | 62 (42.8) | 84 (47.5) | ||
MM type | 0.095 | 0.101 | |||||
IgG | 69 (39.0) | 76 (53.1) | 102 (57.8) | 77 (53.1) | 103 (58.1) | ||
Non-IgG | 108 (61.0) | 67 (46.9) | 75 (42.2) | 68 (46.9) | 74 (41.9) | ||
Previous hematopoietic stem cell transplant | 0.037 | 0.083 | |||||
Yes | 118 (66.7) | 113 (79.0) | 142 (80.5) | 114 (78.6) | 145 (81.9) | ||
No | 59 (33.3) | 30 (21.0) | 35 (19.5) | 31 (21.4) | 32 (18.1) |